Citigroup Maintains Buy on Edwards Lifesciences, Lowers Price Target to $77
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch maintains a Buy rating on Edwards Lifesciences but lowers the price target from $83 to $77.
October 01, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Edwards Lifesciences but reduces the price target from $83 to $77, indicating a slightly less optimistic outlook.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates a tempered outlook, likely due to revised expectations or market conditions. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100